Table 1 Demographic and clinical characteristics of the participants in the JUPITER cohort

All subjects, n (%)

̶

500

116 (23.2)

194 (38.8)

78 (15.6)

11 (2.2)

26 (5.2)

61 (12.2)

14 (2.8)

Sex, female, n (%)

500

289 (57.8)

31 (26.7)

130 (67.0)

62 (79.5)

9 (81.8)

15 (57.7)

30 (49.2)

12 (85.7)

Age at JIA diagnosis, years, mean ± SD

500

8.8 ± 4.7

12.1 ± 2.9

6.5 ± 4.3

8.6 ± 4.5

11.6 ± 4.6

10.5 ± 3.4

7.5 ± 4.7

11.8 ± 3.5

Disease duration, years, mean ± SD

500

4.0 ± 1.9

3.6 ± 1.6

4.2 ± 2.0

4.6 ± 2.1

5.0 ± 2.3

3.2 ± 1.8

4.4 ± 2.9

2.4 ± 1.0

Comorbidities, n (%)

500

102^a

20 (17.3)

28 (14.4)

13 (16.7)

0 (0)

15 (57.7)

14 (23.0)

2 (14.3)

FMF

63 (12.6)

19 (16.4)

26 (13.4)

6 (7.7)

0 (0)

0 (0)

10 (16.4)

2 (14.3)

Osteoporosis

8 (%1.6)

0 (0)

2 (1.0)

5 (6.4)

0 (0)

0 (0)

1 (1.7)

0 (0)

Delayed puberty^c

6 (%1.2)

1 (0.9)

0 (0.9)

2 (2.6)

0 (0)

0 (0)

3 (4.9)

0 (0)

ANA positivity, n (%^b)

396

191 (48.2)

10 (15.9)

127 (68.3)

31 (40.8)

2 (25)

8 (38.1)

9 (23.1)

4 (33.3)

HLA-B27 positivity, n (%^b)

168

56 (33.3)

47 (51.7)

2 (5.9)

̶

̶

4 (23.5)

̶

3 (23.1)